|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Characteristics of postintensive care syndrome in survivors of pediatric critical illness: A systematic review显示文摘AIM To synthesize the available evidence focusing on morbidities in pediatric survivors of critical illness that fall within the defined construct of postintensive care syndrome(PICS) in adults, including physical, neurocognitive and psychological morbidities.METHODS A comprehensive search was conducted in MEDLINE, EMBASE, the Cochrane Library, Psyc INFO, and CINAHL using controlled vocabulary and key word terms to identify studies reporting characteristics of PICS in pediatric intensive care unit(PICU) patients. Two reviewers independently screened all titles and abstracts and performed data extraction. From the 3176 articles identified in the search, 252 abstracts were identified for full text review and nineteen were identified for inclusion in the review. All studies reporting characteristics of PICS in PICU patients were included in the final synthesis. RESULTS Nineteen studies meeting inclusion criteria published between 1995 and 2016 were identified and categorized into studies reporting morbidities in each of three categories-physical, neurocognitive and psychological. The majority of included articles reported prospective cohort studies, and there was significant variability in the outcome measures utilized. A synthesis of the studies indicate that morbidities encompassing PICS are well-described in children who have survived critical illness, often resolving over time. Risk factors for development of these morbidities include younger age, lower socioeconomic status, increased number of invasive procedures or interventions, type of illness, and increased benzodiazepine andnarcotic administration.CONCLUSION PICS-related morbidities impact a significant proportion of children discharged from PICUs. In order to further define PICS in children, more research is needed using standardized tools to better understand the scope and natural history of morbidities after hospital discharge. Improving our understanding of physical, neurocognitive, and psychological morbidities after critical illness in the pediatric population is imperative for designing interventions to improve long-term outcomes in PICU patients. | Elizabeth A Herrup Beth Wieczorek Sapna R Kudchadkar | 2017 | World Journal of Critical Care Medicine2017，6，2： | 7 |
| 2 | Adjuvant therapy for melanoma:a surgical perspective显示文摘 | Sondak VK Gonzalez RJ Kudchadkar R | | 0，，01： | 1 |
| 3 | Propofol monotherapy for neonatal intubation provides high risk but few benefits 显示文摘 | Kudchadkar SR Nemergut ME | 2014 | Acta Paediatr2014，103，11： | 1 |
| 4 | BRAF mutations:signaling,epidemiology,and clinical experience in multiple malignancies显示文摘 | HALL R D KUDCHADKAR R R | 2014 | Cancer Control2014，21，： | 1 |
| 5 | Adjuvant therapy for melanoma:a suegical perspective显示文摘 | Sonak VK Gonzalez RJ Kudchadkar R | 2011 | Sueg Oncol Clin N Am2011，20，1： | 1 |
| 6 | Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer显示文摘 | Kudchadkar R O' Regan RM | 2005 | CA Cancer J Clin2005，55，3： | 1 |
| 7 | Safety, efficacy, and bio- markers of nivolumab with vaccine in ipilimumab-refractory or- naive melanoma 显示文摘 | Weber J S Kudchadkar RR Yu B | 2013 | J Clin Oncol2013，31，34： | 1 |
| 8 | Safety, efficacy, and bio- markers of nivolumab with vaccine in ipilimumab-refractory or - naive melanoma显示文摘 | Weber JS Kudchadkar RR Yu B | 2013 | J Clin Oncol2013，31，34： | 1 |
| 9 | Phase 2,multicenter,safety and efficacy study of pidilizumab in patients with metastatic melanoma 显示文摘 | ATKINS M B KUDCHADKAR R R SZNOL M | 2014 | J Clin Oncol2014，，： | 1 |
| 10 | Ipilimumab 显示文摘 | Sondak V K Smalley K S Kudchadkar R | 2011 | Nat Rev Drug Discov2011，10，6： | 1 |
| 11 | Laparoscopic pelvic exenteration for advanced pelvic cancer:a review of 16 cases显示文摘 | Puntambekar S Kudchadkar RJ Gurjar AM | 2006 | Gynecol Oncol2006，102，3： | 1 |
| 12 | A phase IB study of ipilimumab with peginterferon alfa -2b for pa- tients with unresectable stages 1 B/C/IV melanoma 显示文摘 | KUDCHADKAR R R GIBNEY G T DORMAN D | 2014 | J Clin Oncol2014，32，15： | 1 |
| 13 | Safety, efficacy, and biomar-kers of nivolumab with vaccine in ipilimumab rrfractory or -naive mela-noma显示文摘 | Weber JS Kudchadkar RR Yu | 2013 | J Clin Oncol2013，31，34： | 1 |
| 14 | Safety,corre- lative markers,and clinical results of adjuvant nivolumab in combination with vaccine in reseeted high-risk metastatic me- lanoma显示文摘 | Gibney GT Kudchadkar RR DeConti RC | 2015 | Clinical Cancer Research2015，21，4： | 1 |
| 15 | Esopha- go-diverticulo-pericardial fitula显示文摘 | Kudchadkar A Markovitz W Moqtaderi FF | 2008 | N Y State J Med2008，80，6： | 1 |
| 16 | Laparoscopie pelvic exenteration for advanced pelvic cancer:, a review of 16 cases显示文摘 | PUNTAMBEKAR S KUDCHADKAR RJ GURJAR AM | 2006 | Gynecol Oncol2006，102，3： | 1 |
| 17 | Targeted therapy in melanoma 显示文摘 | Kudchadkar RR Smalley KS Glass LF | 2013 | Glin Dermatol2013，31，2： | 1 |
| 18 | Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors 显示文摘 | Kudchadkar R Lewis K Gonzalez R | 2012 | Semin Oncol2012，39，2： | 1 |
| 19 | BRAF mutations: signaling, epidemiolo- gy, and clinical experience in multiple malignancies显示文摘 | Hall RD Kudchadkar RR | 2014 | Cancer Con- trol2014，21，3： | 1 |
| 20 | Balancing In- flammation:The Link between Thl7 and Regulatory T Ceils 显示文摘 | Diller ML Kudchadkar RR Delman KA | 2016 | Mediators Inflamm2016，2016，63： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员